传统的医院里光照有一定效果，现在临床试验IL-17抑制剂有疗效（见内）

https://patents.google.com/patent/WO2017221174A1/en

Methods of treating vitiligo using interleukin-17 (il-17) antibodies

 

Abstract

The present disclosure relates to methods for treating vitiligo using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating vitiligo patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

 

 

Classifications

 C07K16/244 Interleukins [IL]

View 5 more classifications

WO2017221174A1

WIPO (PCT)

 Download PDF  Find Prior Art  Similar

Other languages

French

Inventor

Joel Gelfand

---

Worldwide applications

2017  WO

---

Application PCT/IB2017/053701 events 

2016-06-22

 

Priority to US201662353121P

2016-06-22

 

Priority to US62/353,121

2017-06-21

 

Application filed by Novartis Ag

2017-12-28

 

Publication of WO2017221174A1

---

Info

Patent citations (9)

 

Non-patent citations (27)

 

Cited by (1)

 

Legal events

 

Similar documents

 

Priority and Related Applications

External links

Espacenet

Global Dossier

PatentScope

Discuss

 

Description

METHODS OF TREATING VITILIGO USING INTERLEUKIN-17 (IL-17) ANTIBODIES

RELATED APPLICATIONS

The instant application claims priority to US Provisional Patent application No.

62/348217, filed June 10, 2016, which is incorporated by reference herein in its entirety.

TECHNICAL FIELD

The present disclosure relates to methods for treating vitiligo, using IL-17 antagonists, e.g., an IL-17 antibody or antigen-binding fragment thereof, such as secukinumab.